The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...
Abbott is putting the old adage that “good things come in threes” to the test, with its fourth FDA approval in less than a year for its spinal cord stimulation (SCS) systems. The latest regulatory nod ...
University Orthopedics’ East Bay Surgery Center in East Providence, R.I., has become the first site in the state to implant a closed-loop spinal cord stimulator. Shiqiang “Chris” Tian, MD, an ...
On May 16, 2023, the U.S. Food and Drug Administration (FDA) approved spinal cord stimulation (SCS) devices from the pharmaceutical company Abbott to treat chronic back pain in people who have not had ...
The FDA has cleared home use of a device that helps people with spinal cord injuries regain mobility and functioning.
DUBLIN, Dec. 9, 2019 /PRNewswire/ -- The "Global Spinal Cord Stimulation (SCS) Market: Size, Trends & Forecasts (2019-2023)" report has been added to ResearchAndMarkets.com's offering. Global Spinal ...
The suits cite the U.S. Supreme Court’s 2024 decision in Loper Bright Enterprises v. Rainmondo in naming the FDA as a defendant. The lawsuits allege the devices should require pre-market approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback